Targeted radionuclide treatment for selected patients with bone metastases.
Request Medical OpinionAdvanced treatment information for international patients and healthcare professionals.
Radium-223 is a targeted alpha therapy used for selected patients with symptomatic bone metastases.
It is commonly evaluated in selected prostate cancer patients with bone-dominant metastatic disease.
Eligibility depends on cancer type, bone involvement, blood count and previous treatments.
Session number and schedule are determined by nuclear medicine and oncology specialists.
Pain control, bone health and laboratory monitoring may be part of the care plan.
It may help target bone metastases within the overall oncology treatment plan.
Bone scan, PET/CT, CT, MRI, PSA and recent laboratory results may be required.
Suitability and final protocol can only be confirmed after specialist evaluation.
Patients should submit medical reports, imaging files, pathology results, previous treatment history and current clinical information.
Our team organizes the case and coordinates specialist evaluation before treatment planning, estimated duration and quotation.
Submit Your ReportsTreatment suitability, protocol, number of sessions, hospital stay and cost depend on diagnosis, disease stage, previous treatments and specialist evaluation.
Send your reports and receive professional treatment planning support.